CRL CHARLES RIVER LABORATORIES

2026Q1 · CUSIP 159864107 · Sector: Healthcare & Biotech

Danger · Dual-confirm: breadth + price

Holders

556

Δ holders QoQ

-28

Breadth percentile

Top 95%

Whale holders

231

Δ whales

-7

Inst. holding value

$9.8B

New positions

Closed positions

101

Price momentum (1Q)

-5.4%

Put / Call

8/7

Breadth history (34 quarters)

Period	Percentile	Next-1Q return	Next-2Q return
2025Q4	Top 18%	-5.4%	—
2025Q3	Top 7%	+0.9%	-4.1%
2024Q1	Top 6%	-7.9%	-15.3%
2023Q3	Top 15%	+26.0%	+17.7%
2022Q4	Top 7%	-21.6%	-21.8%
2021Q4	Top 18%	-26.3%	-27.9%
2021Q3	Top 2%	-22.7%	-43.0%
2021Q2	Top 1%	-7.2%	-21.3%
2020Q4	Top 12%	+12.5%	+45.1%
2020Q3	Top 9%	+22.9%	+34.0%
2020Q2	Top 5%	+9.4%	+37.1%
2018Q4	Top 4%	-8.8%	-7.4%
2018Q3	Top 17%	+8.8%	-1.1%
2018Q2	Top 16%	+6.7%	+17.0%

Show all 14 events

Put holders

QoQ: +1

Call holders

QoQ: +1

See methodology →

PE (TTM)

—

EPS (TTM)

$-3.71

EPS YoY

—

Revenue (TTM)

$4.0B

Revenue YoY

+0.1%

Quarterly Revenue & EPS (4Y)

Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable

P/E (TTM) over time

P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden

As of 2026-03-28 · SEC filings (XBRL)